BACKGROUND: We compared perceptions regarding risk of cardiovascular events and benefits of cardiovascular disease (CVD) risk factor reduction between patients with peripheral arterial disease (PAD), patients with coronary artery disease (CAD), and patients without atherosclerosis (no disease). METHODS: Participants with no disease (n = 142) had a normal ankle-brachial index and no clinically evident atherosclerosis (group 1). The PAD participants (n = 136) had an ankle-brachial index less than 0.90 and no other clinically evident atherosclerosis (group 2). Participants with CAD (n = 70) had a normal ankle-brachial index and a history of heart disease (group 3). Participants were interviewed regarding risk of mortality, CVD, and the importance of CVD risk factor reduction for hypothetical patients with PAD and CAD. RESULTS: All groups reported that risks of myocardial infarction, stroke, and death were higher for a patient with CAD than for a patient with PAD. Group 2 was less likely than group 3 to believe that PAD is associated with an extremely high risk of stroke (13.3% vs 28.7%; P =.005) or mortality (10.9% vs 26.6%; P =.003). Group 2 was less likely than group 1 to believe that a patient with PAD has a very high risk of myocardial infarction (13.1% vs 23.8%; P =.02), stroke (13.3% vs 27.5%; P =.003), or mortality (10.9% vs 24.3%; P =.004). Compared with group 3, a smaller percentage of patients in group 2 reported that cholesterol lowering was very important in PAD (57.5% vs 75.8%; P =.005). CONCLUSIONS: Compared with other patients, those with PAD underestimated the high risk of cardiovascular events associated with PAD and the benefits of cholesterol-lowering therapy. These findings may help explain the low rates of CVD risk factor control previously reported in patients with PAD.
BACKGROUND: We compared perceptions regarding risk of cardiovascular events and benefits of cardiovascular disease (CVD) risk factor reduction between patients with peripheral arterial disease (PAD), patients with coronary artery disease (CAD), and patients without atherosclerosis (no disease). METHODS:Participants with no disease (n = 142) had a normal ankle-brachial index and no clinically evident atherosclerosis (group 1). The PAD participants (n = 136) had an ankle-brachial index less than 0.90 and no other clinically evident atherosclerosis (group 2). Participants with CAD (n = 70) had a normal ankle-brachial index and a history of heart disease (group 3). Participants were interviewed regarding risk of mortality, CVD, and the importance of CVD risk factor reduction for hypothetical patients with PAD and CAD. RESULTS: All groups reported that risks of myocardial infarction, stroke, and death were higher for a patient with CAD than for a patient with PAD. Group 2 was less likely than group 3 to believe that PAD is associated with an extremely high risk of stroke (13.3% vs 28.7%; P =.005) or mortality (10.9% vs 26.6%; P =.003). Group 2 was less likely than group 1 to believe that a patient with PAD has a very high risk of myocardial infarction (13.1% vs 23.8%; P =.02), stroke (13.3% vs 27.5%; P =.003), or mortality (10.9% vs 24.3%; P =.004). Compared with group 3, a smaller percentage of patients in group 2 reported that cholesterol lowering was very important in PAD (57.5% vs 75.8%; P =.005). CONCLUSIONS: Compared with other patients, those with PAD underestimated the high risk of cardiovascular events associated with PAD and the benefits of cholesterol-lowering therapy. These findings may help explain the low rates of CVD risk factor control previously reported in patients with PAD.
Authors: Roberta K Oka; Michael S Conte; Christopher D Owens; Joseph Rapp; Gordon Fung; Hugh F Alley; John C Giacomini; Jonathan Myers; Emile R Mohler Journal: Vasc Med Date: 2012-02 Impact factor: 3.239
Authors: Mary M McDermott; George Reed; Philip Greenland; Kathy M Mazor; Sherry Pagoto; Judith K Ockene; Rex Graff; Philip A Merriam; Kathy Leung; Larry Manheim; Melina R Kibbe; Barbara Olendzki; William H Pearce; Ira S Ockene Journal: Am J Med Date: 2011-06 Impact factor: 4.965
Authors: Nina Byskosh; Vivek Pamulapati; Shujun Xu; Ashley K Vavra; Andrew W Hoel; Lu Tian; Mary M McDermott; Zeeshan Butt; Karen J Ho Journal: J Vasc Surg Date: 2021-11-15 Impact factor: 4.268
Authors: Raimund Erbel; Stefan Möhlenkamp; Karl-Heinz Jöckel; Nils Lehmann; Susanne Moebus; Barbara Hoffmann; Axel Schmermund; Andreas Stang; Johannes Siegrist; Nico Dragano; Dietrich Grönemeyer; Rainer Seibel; Klaus Mann; Martina Bröcker-Preuss; Knut Kröger; Lothar Volbracht Journal: Dtsch Arztebl Int Date: 2008-01-07 Impact factor: 5.594
Authors: Uwe Zeymer; Klaus G Parhofer; David Pittrow; Christiane Binz; Markus Schwertfeger; Tobias Limbourg; Joachim Röther Journal: Clin Res Cardiol Date: 2009-02-16 Impact factor: 5.460
Authors: I Vaartjes; G J de Borst; J B Reitsma; A de Bruin; F L Moll; D E Grobbee; M L Bots Journal: BMC Cardiovasc Disord Date: 2009-08-28 Impact factor: 2.298